Literature DB >> 19731767

Immune response to measles vaccine after mass vaccination in Urmia, Islamic Republic of Iran.

Z Yekta1, R Pourali, M R Taravati, S Shahabi, S Salary, F Khalily, A Farzin.   

Abstract

We investigated the effectiveness of the mass measles vaccination campaign in Urmia, Islamic Republic of Iran, by examining the measles IgG seroprevalence and antibody response from paired data before and after the campaign. The overall seropositive rate of 624 subjects aged 5-25 years increased 1 year after the mass vaccination (from 53.0% to 72.3%). A rise in antibody titre occurred in all age groups except the 21-25 years group, which had the highest titre before mass vaccination. On logistic regression analysis, only immune status prior to vaccination was significantly associated with the seroresponse. It may be cost-effective to check antibody titres before mass vaccinations, especially in high vaccine coverage regions with circulating wild virus.

Mesh:

Substances:

Year:  2009        PMID: 19731767

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  3 in total

1.  Seroprevalence of measles, mumps & rubella antibodies among 5-10 years old children in north India.

Authors:  Madhu Gupta; Jaya Prasad Tripathy; Madhur Verma; Mini P Singh; Ramanpreet Kaur; R K Ratho; Rajesh Kumar
Journal:  Indian J Med Res       Date:  2019-03       Impact factor: 2.375

2.  Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran.

Authors:  Hana Saffar; Maryam Khalifeloo; Mohammad-Jafar Saffar; Alireza Abdollahi; Mohammad-Reza Parsaei; Gholam-Reza Ghorbani; Samaneh Salarvand; Mohsen Aarabi
Journal:  BMC Infect Dis       Date:  2021-03-25       Impact factor: 3.090

3.  Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign.

Authors:  Behnam Honarvar; Mohsen Moghadami; Afagh Moattari; Amir Emami; Neda Odoomi; Kamran Bagheri Lankarani
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.